Vitexin Activates Mitophagy to Shield Kidneys from Ischemia-Reperfusion Damage
A natural flavonoid from Vitex plants reduces kidney injury by boosting mitochondrial cleanup via the p38/MAPK pathway.
Summary
Researchers tested vitexin, a plant-derived flavonoid, in mouse kidney ischemia-reperfusion (I/R) models and human HK-2 cell hypoxia-reoxygenation models. Vitexin pretreatment (20 mg/kg/day for 7 days) reduced oxidative stress markers, cell apoptosis, and kidney injury biomarkers (KIM-1, NGAL) while improving creatinine and BUN levels. Network pharmacology and molecular docking pointed to the p38/MAPK pathway as a key target. Western blotting and immunofluorescence confirmed that vitexin suppresses p38 phosphorylation, which in turn enhances mitophagy—the selective removal of damaged mitochondria—thereby protecting renal tubular cells. These findings position vitexin as a candidate therapeutic for kidney transplant-related IRI.
Detailed Summary
Renal ischemia-reperfusion injury (IRI) is an unavoidable complication of kidney transplantation and is worsening as clinicians increasingly use marginal donor organs. During ischemia, mitochondria in proximal tubular cells are damaged; upon reperfusion, they flood cells with reactive oxygen species (ROS), triggering apoptosis and inflammation. Mitophagy—selective autophagic clearance of dysfunctional mitochondria—is a known protective response, but pharmacological strategies to harness it remain limited. This study investigated whether vitexin, a natural C-glucosyl flavone from Vitex leaves, could enhance mitophagy and reduce renal IRI.
The team used two complementary models: HK-2 human proximal tubular cells subjected to 24-hour hypoxia followed by reoxygenation (H/R), and male C57BL/6J mice with bilateral renal pedicle clamping for 45 minutes followed by 24-hour reperfusion. Vitexin (20 mg/kg/day i.p.) was administered for 7 days before surgery. Network pharmacology cross-referenced vitexin targets from ChEMBL, SEA, and SwissTargetPrediction databases against mitophagy-related and renal IRI gene sets from GeneCards and OMIM, followed by KEGG pathway enrichment and molecular docking to identify mechanistic candidates.
Vitexin treatment significantly improved renal function, lowering serum creatinine and BUN in I/R mice. Histological scoring showed markedly reduced tubular injury (cell lysis, cast formation, brush border loss). TUNEL assays confirmed decreased apoptosis in renal tissue. At the molecular level, vitexin reduced BAX and cleaved caspase-3 while elevating BCL-2, indicating anti-apoptotic effects. Oxidative stress markers improved: MDA levels fell and SOD activity rose in treated kidneys. Intracellular and mitochondrial ROS (measured by DCFH-DA and MitoSOX Red) were both reduced in H/R-challenged HK-2 cells pretreated with vitexin.
Network pharmacology analysis identified MAPK14 (p38) as a top-ranked intersection target among vitexin targets, mitophagy genes, and renal IRI genes. Molecular docking showed favorable binding between vitexin and p38. Western blotting validated that vitexin suppressed p38 phosphorylation in both cell and animal models. Critically, mitophagy markers responded accordingly: LC3B-II/I ratio increased, p62 decreased (indicating autophagic flux), and TOMM20 expression fell (reflecting mitochondrial turnover). Immunofluorescence co-localization of LC3B with the mitochondrial marker COX IV confirmed enhanced mitophagy in vitexin-treated kidney sections. Conversely, pharmacological activation of p38 with anisomycin reversed vitexin's mitophagy-promoting and cytoprotective effects, directly linking p38 suppression to the protective mechanism.
These results establish a mechanistic chain: vitexin → p38 phosphorylation inhibition → enhanced mitophagy → reduced ROS and apoptosis → preserved renal tubular function. The study is limited by its preclinical scope and relatively small animal group sizes (n=3 per group), and the precise binding mode of vitexin to p38 requires crystallographic confirmation. Nonetheless, vitexin's natural origin, established safety profile, and multi-faceted protective actions make it a compelling candidate for further translational investigation in kidney transplantation settings.
Key Findings
- Vitexin pretreatment reduced serum creatinine, BUN, and histological tubular injury scores in mouse renal I/R models.
- Vitexin suppressed p38 MAPK phosphorylation, identified via network pharmacology as the key mechanistic target.
- Mitophagy markers LC3B-II, p62 flux, and TOMM20 confirmed that p38 inhibition by vitexin enhances mitochondrial autophagy.
- Oxidative stress (MDA, ROS) decreased and antioxidant capacity (SOD) increased in vitexin-treated kidneys and cells.
- p38 activator anisomycin reversed vitexin's protective effects, causally linking p38 suppression to renal protection.
Methodology
The study combined in vitro HK-2 cell hypoxia-reoxygenation models and in vivo bilateral renal pedicle clamping in C57BL/6J mice (n=3/group), with vitexin dosed at 20 mg/kg/day i.p. for 7 days pre-surgery. Mechanism was elucidated through network pharmacology, molecular docking, Western blotting, TUNEL, immunofluorescence, and ROS fluorometric assays.
Study Limitations
Animal groups were very small (n=3 per group), limiting statistical power and generalizability. All experiments are preclinical; no pharmacokinetic, dosing-safety, or human translational data are presented. The molecular docking binding pose is predictive and lacks experimental structural validation (e.g., X-ray crystallography or cryo-EM).
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.